Cyprumed, MSD Sign Deal for Oral Peptide Therapeutics
Cyprumed GmbH, a dedicated drug delivery company specializing in innovative oral peptide formulations, and MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA), today...
Tag : commercialization
ABL Bio Licenses Grabody-B Platform to GSK for Brain Drugs
ABL Bio and GSK enter into a multi-program agreement to develop novel medicines for neurodegenerative diseases Programs will leverage ABL Bio’s Grabody-B platform technology to effectively deliver molecules across...
Spiritus Expands Direct Air Capture Team with Top Clean Energy Hires
Industry veterans from Babcock & Wilcox, LanzaTech, and other major players join Spiritus to bridge the gap between pilot and large-scale deployment Spiritus, the company...
PHC and Cyfuse Develop New Tech for 3D Cell Product Production
Breakthrough Will Support Development of New Circulation Cell Culture System to Enhance Quality and Stability of Manufacturing PHC Corporation (Headquarters: Chiyoda-ku, Tokyo; President: Nobuaki Nakamura;...
Xeltis Adds Leading Experts to Medical Advisory Board
Leading nephrologists Dr. An De Vriese and Dr. Monnie Wasse join as Company continues clinical advancement Xeltis, a leading developer of transformative implants that enable the natural...
Nielsen BioSciences Completes Enrollment in Phase 3 CANDIN Trial
325 subjects enrolled across the United States and Japan in the first Phase III clinical trial for the treatment of warts in children and adults....
CareDx Study: AlloSeq cfDNA Accurately Detects Organ Rejection
AlloSeq cfDNA Consistent with Performance of Proven AlloSure Testing CareDx Brings Innovative Non-Invasive Transplant Monitoring to Patients Internationally with AlloSeq cfDNA CareDx, Inc. (Nasdaq: CDNA)...
KORU Medical Announces Phase III Trial for New Nephrology Drug
KORU Medical Systems (NASDAQ: KRMD) (“KORU Medical” or the “Company”), a leading medical technology company focused on the development, manufacturing, and commercialization of innovative and...